Thyroid tumors often become resistant to this treatment method through loss of proper targeting of NIS to the plasma membrane rather than loss of NIS function, making the mechanism of NIS trafficking a potential target for cancer therapy (Martín et al., 2019). Here, SLC5A5 is linked to cancer.